Literature DB >> 2455191

Modulation of neuroeffector transmission.

M J Rand1, H Majewski, H Wong-Dusting, D F Story, R E Loiacono, J Ziogas.   

Abstract

Local mechanisms that regulate transmitter release at autonomic neuroeffector junctions may be classified into four main types: (a) Automodulation, involving a feedback effect of the transmitter on receptors associated with the prejunctional terminals resulting in a restraint on the facilitation of release that occurs when a train of nerve impulses invades the terminals. Changes in the composition of the transmitter, such as the presence of adrenaline as a cotransmitter together with noradrenaline, can result in increased facilitation of transmission. (b) Transneuronal modulation involving an effect of the transmitter released from terminals of one type on adjacent terminals of another type; thus, noradrenaline release may be inhibited by acetylcholine released from cholinergic nerve terminals adjacent to the noradrenergic terminals. (c) Transjunctional modulation involving a feedback effect on the prejunctional nerve terminals of one or more factors released from effector cells. Such substances include adenyl compounds (adenosine and/or ATP) and metabolites of arachidonic acid. (d) Hormonal modulation involving the action of blood-borne hormones or locally generated hormone-like substances on prejunctional terminals. Some of the substances involved in modulation may act in more than one way; thus, opioids may function as cotransmitters or as hormones, and adenyl compounds may be cotransmitters or be released from effector cells. The effects of exogenous drugs on the substances involved in the modulation of transmission and on the prejunctional receptors for these substances account for many anomalous actions of drugs used or proposed for use in therapeutics.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2455191

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  Pharmacological profile of the 5-HT-induced inhibition of cardioaccelerator sympathetic outflow in pithed rats: correlation with 5-HT1 and putative 5-ht5A/5B receptors.

Authors:  Araceli Sánchez-Lopez; David Centurión; Erika Vázquez; Udayasankar Arulmani; Pramod R Saxena; Carlos M Villalón
Journal:  Br J Pharmacol       Date:  2003-09-22       Impact factor: 8.739

2.  Characterization of prejunctional 5-HT receptors mediating inhibition of sympathetic vasopressor responses in the pithed rat.

Authors:  C M Villalón; J Contreras; E Ramírez-San Juan; C Castillo; M Perusquía; J A Terrón
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

3.  Evidence for 5-HT(1B/1D) and 5-HT(2A) receptors mediating constriction of the canine internal carotid circulation.

Authors:  D Centurión; M I Ortiz; A Sánchez-López; P De Vries; P R Saxena; C M Villalón
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

4.  Inhibitory prejunctional muscarinic receptors at sympathetic nerves do not operate through a cyclic AMP dependent pathway.

Authors:  M Costa; H Majewski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-12       Impact factor: 3.000

5.  The 5-HT1-like receptor mediating the increase in canine external carotid blood flow: close resemblance to the 5-HT1D subtype.

Authors:  C M Villalón; J A Terrón
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

6.  Pharmacological profile of the receptors that mediate external carotid vasoconstriction by 5-HT in vagosympathectomized dogs.

Authors:  C M Villalón; E Ramírez-San Juan; C Castillo; E Castillo; F J López-Muñoz; J A Terrón
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

7.  Methoxamine enhances the release of endogenous noradrenaline from rabbit ear artery: possible involvement of ATP.

Authors:  R Ishii; K Shinozuka; Y Kobayashi; K Hattori; T Hashimoto; K Takeuchi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.